

Amendments to the Claims

Claim set as follows after Amendment:

1-20 (Canceled)

21. (New) A FLINT analog consisting of residues 1-218 of SEQ ID NO:1.

22. (New) A FLINT analog consisting of residues 1-247 of SEQ ID NO:3.

23. (New) A FLINT analog consisting essentially of residues 1-218 of SEQ ID NO:1.

24. (New) A FLINT analog consisting essentially of residues 1-247 of SEQ ID NO:3.

25. (New) A FLINT fragment comprising residues 1-218 of SEQ ID NO:1.

26. (New) A FLINT fragment comprising residues 1-247 of SEQ ID NO:3.

27. (New) A FLINT analog comprising residues 1-218 of SEQ ID NO:1, said analog having a lower binding affinity for FasL than FLINT.

28. (New) A FLINT analog comprising residues 1-247 of SEQ ID NO:3, said analog having a lower binding affinity for FasL than FLINT.

29. (New) A FLINT analog of claim 23 comprising one or more conservative amino acid substitutions wherein said analog retains anti-apoptotic activity in vivo or in vitro.

30. (New) A FLINT analog of claim 24 comprising one or more conservative amino acid substitutions wherein said analog

retains anti-apoptotic activity in vivo or in vitro.

31. (New) A nucleic acid sequence that encodes residues 1-218 of SEQ ID NO:1.

32. (New) A nucleic acid sequence of claim 31 wherein said sequence comprises residues 1-654 of SEQ OD NO:2.

33. (New) A FLINT analog of claim 27 further characterized by having a binding affinity for LIGHT about the same as the binding affinity of FLINT for LIGHT.

34. (New) A FLINT analog of claim 28 further characterized by having a binding affinity for LIGHT about the same as the binding affinity of FLINT for LIGHT.